Floatz logo

59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Therapeutic assets addressing Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
(+)-Vincristine
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Shanghai Jiao Tong University School of MedicineP4BBB (77)
Cyclophosphamide
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Shanghai Jiao Tong University School of MedicineP4BBB (75)
Bexarotene
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer CenterP4BBB (74)
Dexasone
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2BBB (74)
Fludarabine
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2BBB (73)
Mogamulizumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
University of Michigan Rogel Cancer CenterP4BB (71)
Brentuximab Vedotin
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Assistance Publique - Hôpitaux de ParisP3BB (70)
Lenalidomide
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2BB (70)
4,5,7,4',5',7'-HEXAHYDROXY-2,2'-DIMETHYLNAPHTHODIANTHRONE
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
SoligenixP3BB (69)
Romidepsin
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Walter HanelP2BB (68)
Bendamustine
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer CenterP2BB (67)
VITPSO
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Columbia UniversityP4BB (67)
Pembrolizumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Seda S. ToluP2BB (64)
Resminostat
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
4SC AGP2B (61)
Nivolumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mayo ClinicP2B (60)
Tucidinostat
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Peking Union Medical College HospitalP2B (60)
Durvalumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
University of Michigan Rogel Cancer CenterP1/2B (59)
Belinostat
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2B (58)
Ruxolitinib
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Jonathan BrammerP2B (58)
Kenacort
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer CenterP2B (57)
Venetoclax
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Jonsson Comprehensive Cancer CenterP1/2B (57)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2CCC (53)
L-Leucine, N-(((2S)-4-((4-Methyl-1H-Imidazol-5-Yl)Methyl)-3-Oxo-2-(Phenylmethyl)-1-Piperazinyl)Carbonyl)-
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Prescient Therapeutics, Ltd.P2CCC (53)
Purinostat
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Chengdu Zenitar Biomedical Technology Co., LtdP2CCC (53)
Tapinarof
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Peking University First HospitalP2CCC (53)
Tofacitinib 2% Cream
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer CenterP2CCC (53)
Pralatrexate
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
University of VirginiaP1CCC (50)
Ritlecitinib
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Icahn School of Medicine at Mount SinaiP2CCC (50)
mt-101
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Myeloid TherapeuticsP1/2CCC (48)
Aclarubicin
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Shanghai Jiao Tong University School of MedicineP1/2CC (47)
Duvelisib
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Jonsson Comprehensive Cancer CenterP1/2CC (47)
Linperlisib
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Peking Union Medical College HospitalP1/2CC (47)
Parsaclisib
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Walter HanelP1CC (47)
Prednisone
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Shanghai Jiao Tong University School of MedicineP1/2CC (47)
kt-333
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Kymera Therapeutics, Inc.P1CC (46)
Anti-Icos Monoclonal Antibody Medi-570
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1CC (43)
Autologous Ccr4 Car T Cells
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1CC (43)
BP1002
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Bio-Path Holdings, Inc.P1CC (43)
Cdk-003
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Codiak BioSciencesP1CC (43)
cht101
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and HospitalP1CC (43)
Decitabine
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
University of VirginiaP1CC (43)
Fenretinide
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
SciTech Development, Inc.P1CC (43)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mayo ClinicP1CC (43)
lb1901
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Legend Biotech USA IncP1CC (43)
pf-08046045
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
q702
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mayo ClinicP1CC (43)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mayo ClinicP1CC (43)
Tazemetostat
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1CC (43)
Atlcar.Cd30.Ccr4 Cells
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer CenterP1CC (41)
Bitr2101
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Boston Immune Technologies and TherapeuticsP1CC (41)
Showing 1 to 50 of 59 assets
PreviousPage 1 of 2Next